Summary
- AlloVir intends to raise $251 million in a U.S. IPO of its common stock.
- The firm is developing treatments for various virus-associated conditions, including Covid19.
- While the IPO isn't cheap, ALVR is well positioned to benefit from the increased interest in viral treatment development.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
AlloVir (ALVR) intends to raise $251 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is a mid stage firm developing drug treatments for virus conditions.
ALVR is preparing to enter Phase 3 trials and has an enviable position as a virus-focused biopharma with a promising pipeline in an area that is receiving strong interest by investors, researchers and government entities.
Although the IPO isn’t cheap, for life science investors with a patient hold time frame, the IPO is worth considering.
Company & Technology
Cambridge, Massachusetts-based AlloVir was founded to advance a pipeline of treatment candidates for viruses, including a preclinical stage program for Covid19 virus.
Management is headed by Chief Executive Officer Mr. David Hallal, who has been with the firm since September 2018 and was previously in various executive roles at Alexion Pharmaceuticals, most recently as CEO.
Below is a brief overview video of the BK virus (Hemorrhagic cystitis):
